Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13.09. | SAB Biotherapeutics, Inc.: SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
12.09. | Oppenheimer keeps Outperform rating on SAB Biotherapeutics shares | 1 | Investing.com | ||
09.09. | SAB Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
04.09. | SAB Biotherapeutics, Inc.: SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting | 1 | GlobeNewswire (USA) | ||
12.08. | SAB Biotherapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
09.08. | SAB Biotherapeutics GAAP EPS of -$0.79 | 1 | Seeking Alpha | ||
08.08. | SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates | 126 | GlobeNewswire (Europe) | FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)... ► Artikel lesen | |
08.08. | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
05.08. | SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes | 461 | GlobeNewswire (Europe) | MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing... ► Artikel lesen | |
31.07. | SAB Biotherapeutics names Lucy To as CFO | 1 | Seeking Alpha | ||
31.07. | SAB Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
31.07. | SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer | 103 | GlobeNewswire (Europe) | MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is... ► Artikel lesen | |
27.06. | SAB Biotherapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | SAB Biotherapeutics rebrands as SAB BIO; reaffirms full-year outlook | 1 | Seeking Alpha | ||
20.06. | SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO | 114 | GlobeNewswire (Europe) | New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
18.06. | SAB Biotherapeutics, Inc.: SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions | 1 | GlobeNewswire (USA) | ||
30.05. | SAB Biotherapeutics announces departure of CFO | 1 | Seeking Alpha | ||
30.05. | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Departure of Chief Financial Officer | 181 | GlobeNewswire (Europe) | MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human... ► Artikel lesen | |
21.05. | SAB Biotherapeutics GAAP EPS of -$0.43 beats by $0.60 | 1 | Seeking Alpha | ||
21.05. | SAB Biotherapeutics Gets FDA Clearance To Advance Phase 1 Trial Of SAB-142 In Type-1 Diabetes | 1 | RTTNews |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 102,20 | -0,20 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
CUREVAC | 2,488 | -2,74 % | EQS-News: CureVac präsentiert auf der 39. Jahrestagung der Society for Immunotherapy of Cancer (SITC) | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Konferenz
CureVac präsentiert auf der 39. Jahrestagung der Society for Immunotherapy of Cancer (SITC)
28.10.2024 / 13:00... ► Artikel lesen | |
AMGEN | 291,15 | -1,24 % | Amgen Aktie: Ein echter Erfolgstreiber! | ||
NOVAVAX | 8,280 | -4,43 % | Novavax, Inc.: Åsa Manelius Named Managing Director of Novavax AB Site | GAITHERSBURG, Md., Nov. 4, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that Åsa Manelius... ► Artikel lesen | |
EPIGENOMICS | 1,300 | +44,44 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
BIOGEN | 160,40 | -0,03 % | Biogen Inc.: Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference | -New testing method highlights link between protofibrils and biomarkers for neurodegeneration--Patient and caregiver perspectives on five-year treatment with lecanemab -- Utilization of blood biomarkers... ► Artikel lesen | |
MAINZ BIOMED | 0,206 | -6,38 % | BRISANTE Meldung setzt Mainz Biomed Aktionäre unter Zugzwang. Bitte reagieren Sie jetzt sofort! | ||
INTELLIA THERAPEUTICS | 14,060 | +2,97 % | Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Capital Advisors Inc. OK | ||
VIKING THERAPEUTICS | 58,46 | -14,18 % | AKTIONÄR-Depotwert Gubra: Bald wie Viking Therapeutics? | Die Aktie von Viking Therapeutics hat in der Vorwoche massive Kursgewinne verzeichnet. Vor allem die Aussicht auf weiteren Studiendaten zum Adipositas-Hoffnungsträger VK2735 Anfang November sowie die... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,428 | +12,34 % | Defence Therapeutics Inc.: Defence Therapeutics Completes 1st Tranche of Financing | Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
BIOCRYST PHARMACEUTICALS | 6,500 | -16,43 % | BIOCRYST PHARMACEUTICALS INC - 8-K, Current Report | ||
CARDIOL THERAPEUTICS | 1,772 | +2,90 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research): Buy / Kursziel: USD 8,50 | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH 28.10.2024 / 15:45 CET/CEST Dissemination of a Research, transmitted by EQS News - a service of EQS Group AG.... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 2,261 | +0,58 % | Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology | ||
SAREPTA THERAPEUTICS | 112,60 | -2,00 % | Emerald Advisers LLC Has $1.04 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) | ||
EXELIXIS | 31,330 | -0,51 % | Top-Zahlen: AKTIONÄR-Tipps Neurocrine, Intra-Cellular, Exelixis und Blueprint schießen hoch | Vier laufende AKTIONÄR-Biotech-Tipps. Alle vier erhöhen die Prognose. Alle vier dazugehörigen Aktien gewinnen nach den Ergebnissen prozentual zweistellig. Es gleicht einem Befreiungsschlag, den das... ► Artikel lesen |